Claims
- 1. A therapeutic method for treating an immunoregulatory disease selected from the group consisting of rheumatoid arthritis, systemic lupus erythematosis, Sjogren's Syndrome, multiple sclerosis, chronic lymphocytic leukemia, Type I diabetes, Epstein-Barr virus and AIDS characterized by a depressed autologous mixed lymphocyte response comprising administering to a mammal in need of such treatment an amount of a compound of the Formula I: ##STR9## wherein R.sup.1 is (C.sub.1 -C.sub.5)alkyl, C.sub.3 -C.sub.6 (cycloalkyl)alkyl, C.sub.5 -C.sub.7 (cycloalkenyl)alkyl, aryl, aralkyl, trans(C.sub.4 -C.sub.5)-alkenyl, allyl or furan-2-ylalkyl, R.sup.2 is H, OH or O.sub.2 C(C.sub.1 -C.sub.5)alkyl; R.sup.3 is H, (C.sub.1 -C.sub.5)alkyl; or ((C.sub.1 -C.sub.5)alkyl)-CO; R.sup.4 and R.sup.5 are individually H, F, Cl, Br, NCS, NO.sub.2, NH.sub.2, (C.sub.1 -C.sub.5)alkyl or (C.sub.1 -C.sub.5)alkoxy, or together are benzo; and X is O, S or NY, wherein Y is H, (C.sub.1 -C.sub.5)alkyl or benzyl; and the pharmaceutically acceptable salts thereof; wherein said amount is effective to elevate the AMLR of said mammal.
- 2. The method of claim 1 wherein the mammal is a human.
- 3. The method of claim 2 wherein the immunoregulatory disease is rheumatoid arthritis.
- 4. The method of claim 2 wherein the immunoregulatory disease is systemic lupus erythematosis or Sjogren's Syndrome.
- 5. The method of claim 2 wherein the immunoregulatory disease is multiple sclerosis.
- 6. The method of claim 2 wherein the immunoregulatory disease is chronic lymphocytic leukemia.
- 7. The method of claim 2 wherein the immunoregulatory disease is Type 1 diabetes.
- 8. The method of claim 1 wherein R.sup.1 is C.sub.3 -C.sub.6 -(cycloalkyl)alkyl and R.sup.2 =OH.
- 9. The method of claim 8 wherein R.sup.3 is H.
- 10. The method of claim 9 wherein R.sup.1 is cyclopropylmethyl.
- 11. The method of claim 1 wherein X is NH, O or (benzyl)N.
- 12. The method of claim 1 wherein R.sup.4 and R.sup.5 are H.
- 13. The method of claim 1 wherein R.sup.4 is H and R.sup.5 is 5'-NCS.
- 14. The method of claim 1 wherein the compound of formula I is naltrindole.
- 15. The method of claim 1 wherein the compound of formula I is naltrindole 5'-isocyanate.
- 16. The method of claims 1 or 2 comprising administering the amount of the compound of formula I in a unit dosage form in combination with a pharmaceutically acceptable carrier.
- 17. The method of claim 16 wherein the pharmaceutically acceptable carrier is a liquid.
- 18. The method of claim 16 wherein the unit dosage form comprises a tablet, capsule or solution comprising the compound of formula I.
- 19. The method of claims 1 or 2 wherein the amount of the compound of formula I is administered parenterally.
- 20. The method of claim 19 wherein the amount of the compound of formula I is administered by injection or by intravenous infusion.
- 21. The method of claim 19 wherein the amount of the compound of formula I is administered transdermally.
- 22. The method of claims 1 or 2 wherein the amount of the compound of formula I is administered orally.
Parent Case Info
This is a continuation of application Ser. No. 08/149,039, filed Nov. 8, 1993, U.S. Pat. No. 5,464,541.
Government Interests
The invention was made with the support of NIH Grant No. 2R01-DA01533. The U.S. Government has certain rights in the invention.
US Referenced Citations (3)
Number |
Name |
Date |
Kind |
4816586 |
Portoghese et al. |
Mar 1989 |
|
5244904 |
Nagase et al. |
Sep 1993 |
|
5332818 |
Nagase et al. |
Jul 1994 |
|
Foreign Referenced Citations (1)
Number |
Date |
Country |
0456833A1 |
Nov 1991 |
EPX |
Continuations (1)
|
Number |
Date |
Country |
Parent |
149039 |
Nov 1993 |
|